保护门静脉——从病理生理到临床处理决策

黄志寅; 高锦航

doi:10.3969/j.issn.1001-5256.2021.12.003

保护门静脉——从病理生理到临床处理决策

DOI: 10.3969/j.issn.1001-5256.2021.12.003

黄志寅^a,
高锦航^{a, b, ,}

a.
四川大学华西医院消化内科，成都 610041
b.
四川大学华西医院消化疾病研究室，成都 610041

基金项目:

国家自然科学基金 (81873584);

国家自然科学基金 (82000613);

国家自然科学基金 (82170623);

国家自然科学基金 (82170625);

成都市科技项目 (2017-CY02-00023-GX)

详细信息

通信作者:
高锦航，Gao.jinhang@scu.edu.cn

中图分类号: R575.2
计量
- 文章访问数: 553
- HTML全文浏览量: 162
- PDF下载量: 148
- 被引次数: 0
出版历程
- 收稿日期: 2021-08-04
- 录用日期: 2021-08-31
- 出版日期: 2021-12-20

Protect the portal vein: From pathophysiology to clinical decision making

Zhiyin HUANG^a,
Jinhang GAO^{a, b
, ,}

a.
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, China
b.
Laboratory of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu 610041, China

Research funding:

National Nature Science Foundation of China (81873584);

National Nature Science Foundation of China (82000613);

National Nature Science Foundation of China (82170623);

National Nature Science Foundation of China (82170625);

Chengdu Science and Technology Bureau (2017-CY02-00023-GX)

摘要

摘要: 门静脉系统是肝脏的主要血供系统，肝硬化门静脉高压对门静脉系统的损伤可成为对肝脏的二次打击。保护门静脉才能保障肝脏的充分血供，维护其结构与功能。本文以门静脉生理结构和病理改变为切入点，通过门静脉系统血栓、异常血管新生、肝血窦内稳态失衡三个新的视角，阐述门静脉高压机制及对肝脏的负面影响。倡导改变临床上目前普遍被动应付门静脉高压并发症的现状，鼓励科学探索，多角度、早期降低门静脉高压，避免反复对侧支循环的内镜断流及脾脏切除术，减少各种对门静脉系统损伤的因素，维持门静脉系统的稳态，保护肝脏。
- 高血压, 门静脉 /
- 肝硬化 /
- 静脉血栓形成 /
- 新生血管化, 病理性
Abstract: The portal vein system is the main blood supply system of the liver, and damage to the portal vein system caused by cirrhotic portal hypertension may be the second hit to the liver. Protection of the portal vein will ensure sufficient blood supply of the liver and maintain its structure and function. Starting from the physiological structure and pathological changes of the portal vein, this article elaborates on the adverse effect of portal hypertension on the liver from the three new perspectives of thrombosis of the portal system, abnormal angiogenesis, and disturbance of hepatic sinusoidal homeostasis. It is suggested to change the current status of passive treatment of portal hypertension complications and encourage scientific exploration to reduce portal hypertension from multiple angles as early as possible to avoid repeated endoscopic devascularization of collateral circulation and splenectomy, so as to reduce various factors for the damage of the portal system, maintain the homeostasis of the portal system, and protect the liver.
- Portal Hypertension, Portal Vein /
- Liver Cirrhosis /
- Venous Thrombosis /
- Neovascularization, Pathologic

HTML全文

参考文献(28)

[1]	GRACIA-SANCHO J, CAPARRÓS E, FERNÁNDEZ-IGLESIAS A, et al. Role of liver sinusoidal endothelial cells in liver diseases[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(6): 411-431. DOI: 10.1038/s41575-020-00411-3.
[2]	REVERTER E, CIRERA I, ALBILLOS A, et al. The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery[J]. J Hepatol, 2019, 71(5): 942-950. DOI: 10.1016/j.jhep.2019.07.007.
[3]	BOSCH J, IWAKIRI Y. The portal hypertension syndrome: Etiology, classification, relevance, and animal models[J]. Hepatol Int, 2018, 12(Suppl 1): 1-10. DOI: 10.1007/s12072-017-9827-9.
[4]	HILSCHER MB, SHAH VH. Neutrophil extracellular traps and liver disease[J]. Semin Liver Dis, 2020, 40(2): 171-179. DOI: 10.1055/s-0039-3399562.
[5]	HILSCHER MB, SEHRAWAT T, ARAB JP, et al. Mechanical stretch increases expression of CXCL1 in liver sinusoidal endothelial cells to recruit neutrophils, generate sinusoidal microthombi, and promote portal hypertension[J]. Gastroenterology, 2019, 157(1): 193-209. e9. DOI: 10.1053/j.gastro.2019.03.013.
[6]	LEMMER A, VANWAGNER LB, GANGER D. Assessment of advanced liver fibrosis and the risk for hepatic decompensation in patients with congestive hepatopathy[J]. Hepatology, 2018, 68(4): 1633-1641. DOI: 10.1002/hep.30048.
[7]	TRIPODI A, PRIMIGNANI M, LEMMA L, et al. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis[J]. J Hepatol, 2013, 59(2): 265-270. DOI: 10.1016/j.jhep.2013.03.036.
[8]	SINEGRE T, DURON C, LECOMPTE T, et al. Increased factor Ⅷ plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis[J]. J Thromb Haemost, 2018, 16(6): 1132-1140. DOI: 10.1111/jth.14011.
[9]	CARNEVALE R, RAPARELLI V, NOCELLA C, et al. Gut-derived endotoxin stimulates factor Ⅷ secretion from endothelial cells. Implications for hypercoagulability in cirrhosis[J]. J Hepatol, 2017, 67(5): 950-956. DOI: 10.1016/j.jhep.2017.07.002.
[10]	LOFFREDO L, PASTORI D, FARCOMENI A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: A systematic review and Meta-analysis[J]. Gastroenterology, 2017, 153(2): 480-487. e1. DOI: 10.1053/j.gastro.2017.04.042.
[11]	AMBROSINO P, TARANTINO L, DI MINNO G, et al. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis[J]. Thromb Haemost, 2017, 117(1): 139-148. DOI: 10.1160/TH16-06-0450.
[12]	HUANG ZY, LI J. Splenectomy in patients with liver cirrhosis: The pros and cons[J]. J Prac Hepatol, 2019, 22(4): 459-461. DOI: 10.3969/j.issn.1672-5069.2019.04.002. 黄志寅, 李静. 肝硬化脾切除术利弊权衡细思量[J]. 实用肝脏病杂志, 2019, 22(4): 459-461. DOI: 10.3969/j.issn.1672-5069.2019.04.002.
[13]	GRACIA-SANCHO J, MARRONE G, FERNáNDEZ-IGLESIAS A. Hepatic microcirculation and mechanisms of portal hypertension[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(4): 221-234. DOI: 10.1038/s41575-018-0097-3.
[14]	TAI Y, ZHAO C, ZHANG L, et al. Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress[J]. J Cell Mol Med, 2021, 25: 10389-10402. DOI: 10.1111/jcmm.16968.
[15]	GAO J, WEI B, LIU M, et al. Endothelial p300 promotes portal hypertension and hepatic fibrosis through C-c motif chemokine ligand 2-mediated angiocrine signaling[J]. Hepatology, 2021, 73(6): 2468-2483. DOI: 10.1002/hep.31617.
[16]	TAURA K, de MINICIS S, SEKI E, et al. Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis[J]. Gastroenterology, 2008, 135(5): 1729-1738. DOI: 10.1053/j.gastro.2008.07.065.
[17]	GAO JH, WEN SL, FENG S, et al. Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats[J]. Angiogenesis, 2016, 19(4): 501-511. DOI: 10.1007/s10456-016-9522-9.
[18]	THABUT D, SHAH V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension?[J]. J Hepatol, 2010, 53(5): 976-980. DOI: 10.1016/j.jhep.2010.07.004.
[19]	BOSCH J, GROSZMANN RJ, SHAH VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments[J]. J Hepatol, 2015, 62(1 Suppl): S121-S130. DOI: 10.1016/j.jhep.2015.01.003.
[20]	TANG S, HUANG Z, JIANG J, et al. Celecoxib ameliorates liver cirrhosis via reducing inflammation and oxidative stress along spleen-liver axis in rats[J]. Life Sci, 2021, 272: 119203. DOI: 10.1016/j.lfs.2021.119203.
[21]	GAO JH, WEN SL, TONG H, et al. Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats[J]. Am J Physiol Gastrointest Liver Physiol, 2016, 310(11): G962-G972. DOI: 10.1152/ajpgi.00428.2015.
[22]	KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166. DOI: 10.1038/s41575-020-00372-7.
[23]	ALBILLOS A, de GOTTARDI A, RESCIGNO M. The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577. DOI: 10.1016/j.jhep.2019.10.003.
[24]	CHEN S, LI X, WEI B, et al. Recurrent variceal bleeding and shunt patency: Prospective randomized controlled trial of transjugular intrahepatic portosystemic shunt alone or combined with coronary vein embolization[J]. Radiology, 2013, 268(3): 900-906. DOI: 10.1148/radiol.13120800.
[25]	TRIPATHI D, STANLEY AJ, HAYES PC, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension[J]. Gut, 2020, 69(7): 1173-1192. DOI: 10.1136/gutjnl-2019-320221.
[26]	MAGAZ M, BAIGES A, HERNÁNDEZ-GEA V. Precision medicine in variceal bleeding: Are we there yet?[J]. J Hepatol, 2020, 72(4): 774-784. DOI: 10.1016/j.jhep.2020.01.008.
[27]	LIN J, WEI B, WU H, et al. Effect of antiviral therapy on prognosis of patients with decompensated hepatitis B cirrhosis undergoing transjugular intrahepatic portosystemic shunt[J]. J Clin Hepatol, 2016, 32(2): 254-258. DOI: 10.3969/j.issn.1001-5256.2016.02.011. 林静, 魏波, 吴浩, 等. 抗病毒治疗对失代偿期乙型肝炎肝硬化患者经颈静脉肝内门体分流术预后的影响[J]. 临床肝胆病杂志, 2016, 32(2): 254-258. DOI: 10.3969/j.issn.1001-5256.2016.02.011.
[28]	SENZOLO M, GARCIA-TSAO G, GARCÍA-PAGÁN JC. Current knowledge and management of portal vein thrombosis in cirrhosis[J]. J Hepatol, 2021, 75(2): 442-453. DOI: 10.1016/j.jhep.2021.04.029.